Last updated: October 6, 2026
The neomycin sulfate, polymyxin B sulfate and dexamethasone combination is an established ophthalmic anti-infective and corticosteroid product. Its commercial opportunity is not based on new active-ingredient patents. It is based on formulation performance, preservative strategy, delivery format, supply reliability, and differentiation in ophthalmic and potentially otic markets.
The principal reference product is Maxitrol, marketed by Bausch + Lomb in ophthalmic suspension and ophthalmic ointment forms. The active strengths commonly associated with the ophthalmic suspension are neomycin sulfate equivalent to 3.5 mg/mL neomycin base, polymyxin B sulfate equivalent to 10,000 units/mL, and dexamethasone 1 mg/mL.[1]
What is the approved drug combination used for?
The combination is indicated for steroid-responsive inflammatory ocular conditions when a bacterial infection or risk of bacterial infection exists. It combines two antibacterial agents with dexamethasone, a corticosteroid.
| Component |
Pharmacologic role |
Formulation consideration |
| Neomycin sulfate |
Aminoglycoside antibacterial |
Water-soluble salt; allergy and sensitization risk |
| Polymyxin B sulfate |
Polypeptide antibacterial |
Potency measured in units; compatibility and assay control are important |
| Dexamethasone |
Corticosteroid anti-inflammatory |
Low aqueous solubility; suspension particle control is critical |
The product is a prescription ophthalmic drug. It is not interchangeable with every neomycin, polymyxin B and dexamethasone product marketed for otic use. Route-specific labeling, container closure, sterility, device performance, and clinical instructions control the regulatory pathway.
What excipients are used in the ophthalmic suspension?
The Maxitrol ophthalmic suspension label identifies benzalkonium chloride, polysorbate 20, hypromellose, sodium chloride, hydrochloric acid and/or sodium hydroxide for pH adjustment, and purified water as inactive ingredients.[1]
The excipient system performs several distinct functions:
| Excipient or excipient class |
Primary function |
Commercial significance |
| Benzalkonium chloride |
Preservative |
Enables multidose packaging but creates tolerability and preservative-free differentiation issues |
| Polysorbate 20 |
Wetting and dispersing agent |
Helps distribute hydrophobic or poorly wettable particles |
| Hypromellose |
Suspending and viscosity-enhancing agent |
Supports dose uniformity and ocular residence time |
| Sodium chloride |
Tonicity adjustment |
Helps approximate physiologic osmolality |
| Hydrochloric acid/sodium hydroxide |
pH adjustment |
Supports chemical stability and ocular tolerability |
| Purified water |
Vehicle |
Must meet pharmaceutical quality and microbiological requirements |
The exact excipient concentrations, manufacturing process, particle-size profile, mixing sequence, sterilization approach, and container closure are important parts of the product's quality profile. A formula that reproduces the ingredient list but fails to reproduce suspension uniformity, redispersibility, preservative effectiveness, or delivered dose may not provide a viable generic product.
What excipients are used in the ophthalmic ointment?
The ophthalmic ointment uses mineral oil and white petrolatum as the listed inactive ingredients.[2] The anhydrous base provides prolonged ocular contact and avoids the suspension-control issues associated with an aqueous drop.
The ointment platform has different development priorities:
- Uniform dispersion of all active ingredients in the base.
- Control of particle size and agglomeration.
- Smoothness and absence of grittiness.
- Consistent extrusion from the tube.
- Compatibility between the formulation and tube, tip, and cap.
- Control of microbial contamination during manufacture and filling.
- Acceptable visual blurring and patient handling.
The ointment is commercially relevant because it addresses patients who need longer ocular residence time or cannot reliably administer frequent drops. Its limitations include temporary blurred vision, lower patient convenience, and more difficult dose perception.
What formulation opportunities exist for this drug?
The most credible opportunities are incremental formulation products rather than new chemical entities.
Preservative-free ophthalmic suspension
A preservative-free version could target patients with ocular-surface disease, frequent dosing, contact-lens-related sensitivity, or known intolerance to benzalkonium chloride. The main commercial challenge is packaging. A single-dose vial increases packaging cost and waste. A multidose preservative-free device requires a validated microbial-barrier system and reliable dose delivery over the labeled in-use period.
A preservative-free formulation would require extensive testing of:
- Sterility assurance.
- In-use microbiological protection.
- Extractables and leachables.
- Dose uniformity throughout container use.
- Drop size and residual volume.
- Device compatibility.
- Physical stability after repeated inversion or shaking.
Reduced-preservative or alternative-preservative products
A lower-burden preservative system could occupy a middle position between conventional benzalkonium chloride products and fully preservative-free products. Candidate systems must be evaluated for ophthalmic tolerability, antimicrobial effectiveness, active-ingredient compatibility, and regulatory precedent.
A change from benzalkonium chloride to another preservative is not a simple substitution. It can alter adsorption to packaging, active degradation, pH, surface tension, and antimicrobial performance. The preservative system can also affect drop size and patient-perceived comfort.
Improved suspension technology
Dexamethasone has limited aqueous solubility, so the product depends on suspension engineering. Opportunities include:
- Narrower active-particle size distribution.
- Improved redispersibility after storage.
- Lower sedimentation rate.
- Better dose uniformity between first and last doses.
- Reduced shaking requirement.
- More consistent drop delivery.
- Lower viscosity at the nozzle while preserving ocular residence time.
A formulation with improved redispersibility could provide a practical advantage without changing the active ingredients. The regulatory burden remains substantial because suspension performance is a critical quality attribute.
Ophthalmic gel or in situ gelling system
A gel-forming product could increase residence time and reduce dosing frequency. The commercial tradeoff is higher risk of blurred vision, altered drop delivery, and more complex rheology. Polymer selection must account for preservative interactions, sterilization, active suspension, and ocular comfort.
A gel-based product may have stronger differentiation than a conventional suspension, but it is also more likely to require clinical bridging or a more complex development package.
Ointment modernization
The ointment can be differentiated through:
- Improved extrusion force.
- Smaller and more consistent dose ribbon.
- Lower visual blurring.
- Better active dispersion.
- More convenient tube geometry.
- Improved cap and tip design.
- Unit-dose or low-contamination packaging.
A modern ointment device could compete even where the underlying composition is conventional. Device claims, container-closure claims, and manufacturing controls may provide defensible protection if they are technically specific.
What patent protection covers the product?
The core active combination is old and is not expected to have meaningful remaining composition-of-matter protection. Commercial protection is therefore more likely to arise from formulation, device, process, packaging, and method-of-use claims.
| Protection category |
Likely status or opportunity |
| Neomycin sulfate composition |
Expired or commercially unprotective |
| Polymyxin B sulfate composition |
Expired or commercially unprotective |
| Dexamethasone composition |
Expired or commercially unprotective |
| Basic three-active combination |
Generally mature technology |
| Suspension formulation |
Potentially protectable if technically distinct |
| Preservative-free multidose device |
Potentially protectable |
| Ointment delivery system |
Potentially protectable |
| Manufacturing process |
Protectable where process parameters produce measurable product advantages |
| Method of use |
Limited value unless tied to a specific dosing regimen or patient population |
| Container closure and device |
Potentially protectable, particularly for preservative-free delivery |
Patent strength depends on claim scope and measurable differentiation. A patent that merely recites common ophthalmic excipients in expected concentrations is vulnerable to validity and obviousness challenges. Stronger claims would link a defined formulation or device to a demonstrated technical result, such as improved suspension uniformity, reduced preservative exposure, extended in-use stability, or consistent dosing.
When does this drug lose exclusivity?
The principal reference product is already a mature prescription product. Any historic regulatory exclusivity and basic product patents are not the primary commercial barrier. Generic entry is driven by ANDA approval, product-specific requirements, manufacturing capability, and market access.
For a generic applicant, the key issues are likely to include:
- Establishing pharmaceutical equivalence.
- Demonstrating bioequivalence or the applicable ophthalmic equivalence pathway.
- Matching dosage form and route.
- Meeting sterility and particulate-matter specifications.
- Demonstrating preservative effectiveness where applicable.
- Showing comparable physical characteristics for a suspension.
- Obtaining acceptable therapeutic-equivalence status.
- Managing formulation differences that may affect inactive-ingredient safety.
The FDA Orange Book should be checked for the current NDA, listed patents, pediatric exclusivity, and therapeutic-equivalence designations before any launch or litigation decision.[3] Patent listings can change, and product-specific records should control over general assumptions about expired protection.
What is the Orange Book and FDA regulatory status?
The relevant U.S. regulatory pathway for a conventional generic is generally an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A 505(b)(2) pathway may be considered for a materially different dosage form, delivery system, or formulation where the applicant cannot rely fully on the reference product for an ANDA.
The regulatory distinction is commercially important:
| Development approach |
Typical commercial rationale |
| ANDA ophthalmic suspension |
Lowest differentiation; potentially faster route if pharmaceutical equivalence is achievable |
| ANDA ophthalmic ointment |
Established dosage form with manufacturing complexity |
| 505(b)(2) preservative-free multidose product |
Differentiated device and formulation |
| 505(b)(2) gel or extended-residence product |
Potential dosing or adherence advantage |
| Otic product |
Separate route-specific development and labeling strategy |
Ophthalmic products must address sterility, visible and subvisible particles, extractables, leachables, container closure integrity, delivered volume, and product stability. USP chapters relevant to ophthalmic quality include requirements concerning ophthalmic products and particulate matter.[4]
What Paragraph IV challenges and generic launch risks exist?
A Paragraph IV certification is relevant only if the Orange Book lists an unexpired patent for the reference product. For a mature neomycin sulfate, polymyxin B sulfate and dexamethasone product, the principal risk is not necessarily a blocking composition patent. It is the possibility of later-listed formulation, device, or use patents.
A generic applicant should assess:
- Whether the reference NDA has active listed patents.
- Whether any listed patent claims the suspension, ointment, method of treatment, or device.
- Whether a proposed formulation must contain the same inactive ingredients.
- Whether differences in preservative system create a labeling or safety issue.
- Whether a Paragraph IV notice would trigger litigation.
- Whether a 30-month stay could delay approval.
- Whether a non-infringement or invalidity position is commercially credible.
Generic launch scenarios generally fall into three categories:
| Scenario |
Commercial effect |
| No blocking patent and rapid ANDA approval |
Early price erosion and rapid share loss |
| Patent litigation with no settlement |
Launch timing depends on litigation outcome and court relief |
| Settlement with delayed entry |
Reference product retains defined exclusivity period; generic may receive controlled entry date |
There is no biosimilar pathway for this product because it is a small-molecule combination, not a biologic. Biosimilar risk is therefore inapplicable. The relevant competitors are generic ophthalmic and otic products, branded combination products, and single-agent therapies.
Which companies compete in this market?
The competitive field includes the reference-product manufacturer, generic ophthalmic manufacturers, contract manufacturers, and companies selling adjacent corticosteroid-antibiotic combinations.
Relevant competitive dimensions include:
- Price per milliliter or gram.
- Pharmacy channel coverage.
- Hospital and ambulatory-surgery contracts.
- Availability during antibiotic shortages.
- Preservative-free positioning.
- Ointment versus suspension format.
- Unit-dose versus multidose packaging.
- Manufacturing reliability.
- Physician familiarity and formulary status.
Large generic manufacturers can compete on scale and distribution. Smaller ophthalmic specialists can compete through preservative-free products, devices, or niche packaging. Contract development and manufacturing organizations may create licensing opportunities where they possess sterile ophthalmic filling capacity or proprietary container-closure systems.
What licensing and partnering opportunities exist?
The most attractive licensing assets are likely to be enabling technologies rather than the active ingredients.
Potential deal structures include:
- Licensing a preservative-free multidose container.
- Supplying a validated sterile suspension platform.
- Co-developing a gel or extended-residence formulation.
- Granting regional rights to an ophthalmic generic.
- Transferring an ointment manufacturing process.
- Licensing a device with proven dose uniformity.
- Providing finished-dose manufacturing under a long-term supply agreement.
A partner with established ophthalmic regulatory history can reduce development risk. A partner with sterile filling capacity can reduce capital expenditure. A partner with pharmacy distribution can improve launch economics but may demand price concessions or exclusivity.
How strong is the patent estate for the combination?
The underlying patent estate is likely weak as a barrier to conventional generic entry because the active ingredients and basic dosage forms are longstanding. The strongest defensible positions would come from narrow technical claims supported by comparative data.
A commercially meaningful patent program could target:
- A preservative-free multidose system with validated in-use sterility.
- A defined particle-size distribution that improves dose uniformity.
- A polymer system that improves suspension redispersibility.
- A container closure that reduces contamination and adsorption.
- A low-blur ointment with controlled extrusion.
- A defined manufacturing sequence linked to stability or potency.
- A differentiated dosing regimen supported by clinical evidence.
Broad claims covering routine excipient selection would face higher invalidity risk. Trade secrets may provide more durable protection for mixing order, homogenization, sterile processing, filling parameters, and release testing.
What manufacturing and IP barriers affect commercialization?
Sterile ophthalmic manufacturing is the principal operational barrier. The product requires validated aseptic processing or an appropriate sterilization strategy, environmental monitoring, container-closure integrity, and robust particulate control.
Suspension manufacturing presents additional challenges:
- Active settling during filling.
- Incomplete redispersion.
- Concentration gradients.
- Adsorption to manufacturing equipment.
- Filter incompatibility.
- Particle-size changes during processing.
- Batch-to-batch potency variation.
- Dose variability after storage.
Ointment manufacturing requires control of heating, cooling, mixing, deaeration, active dispersion, and tube filling. Any process patent should be supported by evidence that the claimed process produces a measurable quality benefit.
What is the commercial outlook and revenue exposure?
The conventional product has limited premium potential because the market is mature and generic competition can reduce net pricing quickly. Revenue opportunity is stronger in differentiated formats than in an undifferentiated suspension.
| Product strategy |
Revenue potential |
Development risk |
| Conventional generic suspension |
Low to moderate |
Moderate |
| Conventional generic ointment |
Low to moderate |
Moderate to high |
| Preservative-free unit-dose suspension |
Moderate |
Moderate to high |
| Preservative-free multidose system |
High if differentiated |
High |
| Gel or extended-residence formulation |
Moderate to high |
High |
| Improved ointment device |
Moderate |
Moderate |
| Regional licensing of a sterile product |
Moderate |
Lower for licensee |
| Hospital supply and shortage-resilience strategy |
Moderate |
Operationally intensive |
The principal value drivers are supply continuity, product quality, physician acceptance, and channel access. A small improvement in formulation may not support a premium unless it produces a visible patient or prescriber benefit.
Key Takeaways
- Neomycin sulfate, polymyxin B sulfate and dexamethasone is a mature ophthalmic combination with limited value from basic active-ingredient protection.
- The principal commercial reference products are Maxitrol ophthalmic suspension and ointment.
- The suspension uses benzalkonium chloride, polysorbate 20, hypromellose, sodium chloride, pH adjusters, and purified water.
- The ointment uses mineral oil and white petrolatum.
- The strongest formulation opportunities are preservative-free delivery, improved suspension uniformity, gel systems, and modernized ointment devices.
- Generic risk is driven by ANDA execution, sterile manufacturing, product equivalence, and any current Orange Book patent listings.
- Biosimilar competition does not apply.
- Licensing value is highest in sterile ophthalmic manufacturing, multidose preservative-free devices, and differentiated delivery systems.
- A defensible patent estate would require narrow technical claims supported by comparative formulation and device data.
FAQs
Can a preservative-free version of this combination be developed?
Yes. The main challenge is maintaining sterility throughout the in-use period without benzalkonium chloride. Unit-dose packaging is simpler; preservative-free multidose systems offer greater convenience but require stronger device and microbiological validation.
Is dexamethasone solubility a major formulation problem?
Yes. Dexamethasone contributes to the suspension-development burden. Particle size, wetting, redispersibility, sedimentation, and delivered-dose uniformity are central development parameters.
Can the ophthalmic product be relaunched as an ear-drop product?
Not automatically. An otic product requires route-specific formulation assessment, labeling, manufacturing controls, and regulatory submissions. The ophthalmic label cannot be assumed to support an otic indication.
Does changing benzalkonium chloride create a new patent opportunity?
It can, but a routine preservative substitution is unlikely to provide strong protection by itself. A stronger position would connect the preservative system to a defined technical result, such as improved tolerability, in-use sterility, stability, or packaging performance.
What is the most attractive commercial format?
A preservative-free multidose suspension or a low-blur, patient-friendly ointment device offers the clearest differentiation. A conventional generic suspension is easier to understand commercially but faces heavier price competition.
References
-
Bausch & Lomb Incorporated. (n.d.). Maxitrol (neomycin sulfate, polymyxin B sulfate and dexamethasone) ophthalmic suspension: Prescribing information. DailyMed, U.S. National Library of Medicine.
-
Bausch & Lomb Incorporated. (n.d.). Maxitrol (neomycin sulfate, polymyxin B sulfate and dexamethasone) ophthalmic ointment: Prescribing information. DailyMed, U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Ophthalmic products and particulate matter requirements. USP Convention.
